News Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency Jan 24, 2021 Posted by Ultragenyx
News Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology Jan 24, 2021 Posted by Ultragenyx
News Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency Jan 24, 2021 Posted by Ultragenyx
News CONTINUUS Pharmaceuticals Secures $69.3 Million Government Contract to Manufacture Critical Medicines in the U.S. Jan 22, 2021 Posted by CONTINUUS Pharmaceuticals, Inc.
News Expanded Global Oncology, Functional and Resourcing Services Launched by Catalyst Clinical Research Jan 19, 2021 Posted by Catalyst Clinical Research
Whitepapers Selecting Your Off-site GMP BioPharma Storage Provider Jan 19, 2021 Posted by Masy BioServices
News Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes Jan 19, 2021 Posted by Sumitomo Dainippon Pharma Oncology
News EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia by China National Medical Products Administration Jan 19, 2021 Posted by EdiGene
News Azzur Group is pleased to announce the appointment of Brijesh Patel to the Director of Consulting for Azzur Worcester Jan 15, 2021 Posted by Azzur of New England LLC
